Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for AKBLF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 1.062B
March 31, 2026 1.013B
December 31, 2025 1.013B
September 30, 2025 971.70M
June 30, 2025 919.95M
March 31, 2025 821.81M
December 31, 2024 746.08M
September 30, 2024 761.43M
June 30, 2024 706.94M
March 31, 2024 679.07M
December 31, 2023 658.98M
September 30, 2023 616.34M
June 30, 2023 613.05M
March 31, 2023 600.59M
December 31, 2022 572.34M
September 30, 2022 520.16M
June 30, 2022 532.24M
March 31, 2022 546.87M
December 31, 2021 532.09M
September 30, 2021 516.51M
June 30, 2021 518.14M
March 31, 2021 525.13M
December 31, 2020 518.29M
September 30, 2020 504.59M
June 30, 2020 488.70M
Date Value
March 31, 2020 482.15M
December 31, 2019 477.09M
September 30, 2019 463.89M
June 30, 2019 481.69M
March 31, 2019 489.12M
December 31, 2018 486.98M
September 30, 2018 512.28M
June 30, 2018 518.06M
March 31, 2018 542.33M
December 31, 2017 530.61M
September 30, 2017 437.82M
June 30, 2017 427.53M
March 31, 2017 406.03M
December 31, 2016 407.83M
September 30, 2016 428.32M
June 30, 2016 424.38M
March 31, 2016 422.46M
December 31, 2015 392.59M
September 30, 2015 380.95M
June 30, 2015 371.16M
March 31, 2015 352.21M
December 31, 2014 382.53M
September 30, 2014 397.95M
June 30, 2014 422.02M
March 31, 2014 423.30M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Novo Nordisk A/S 33.84B
H. Lundbeck A/S 4.109B
AstraZeneca PLC 47.33B
ANI Pharmaceuticals, Inc. 597.21M
Corcept Therapeutics, Inc. 705.78M

Shareholders Equity (Quarterly) Related Metrics